Table 3 The impact of intersectoral costs on the total costs of STIs and HIV
Authors | Healthcare costs | Patient/family costs | Productivity (labour) costs | Total intersectoral costs | Total costs (healthcare and intersectoral) | Proportion of intersectoral costs on the total cost (%) |
|---|---|---|---|---|---|---|
Kuhlmann et al. (HIV) | Total healthcare costs: 22,457 €/year [2009-2011] per patient | Patient out-of-pocket costs: 216 €/year per patient | 1,890 €/year per patient | 2,106 €/year per patient | 24,563 €/year per patient | 9 % |
[US$ 2021: 29.437] | [US$ 2021: 283] | [US$ 2021: 2,474] | [US$ 2021: 2,765] | [US$ 2021:32.200] | ||
Lopez-Bastida et al. (HIV) | Total healthcare costs (asymptomatic HIV): 7,148 €/year [2003] per patient | NA | Asymptomatic HIV: 3,383 €/year per patient | 3,383 €/year per patient | Asymptomatic HIV: 10,531 €/year per patient | “Productivity losses for people living with HIV to range between 3,383€ (asymptomatic HIV) and 5,981€ (symptomatic HIV), representing a range of 32-41 % of the total costs.” [as reported in the original study] |
[US$ 2021: 10,611] | [US$ 2021: 5,023] | [US$ 2021: 5,023] | [US$ 2021: 15,635] | |||
Total healthcare costs (symptomatic HIV): 8,508 €/year per patient | Symptomatic HIV: 5,981 €/year per patient | 5,981 €/year per patient | Symptomatic HIV: 14,489 €/year per patient | |||
[US$ 2021: 12,632] | [US$ 2021: 8,879] | [US$ 2021: 8,879] | [US$ 2021: 21,512] | |||
Mostardt et al. (HIV) | Total healthcare costs (SHI): 19,103 €/year [2008] per patient* | NA | Disability-related productivity loss (labour): 489 €/year per patient | 489 €/year per patient | 23,298 €/year per patient | “9 % of total cost from the societal perspective could be attributed to indirect costs [disability, productivity loss].” [as reported in the original study] |
[US$ 2021: 25,865] | [US$ 2021: 662] | [US$ 2021: 662] | [US$ 2021: 31,542] | |||
Long-term productivity loss (labour): 1,294 €/year per patient | 1,294 €/year per patient | |||||
[US$ 2021: 1,752] | [US$ 2021: 1,752] | |||||
Partial productivity loss (labour): 337 €/year per patient | 337 €/year per patient | |||||
[US$ 2021: 456] | [US$ 2021: 456] | |||||
Owusu-Edusei et al. (non-viral) | NA | NA | Average productivity costs (labour) per case/2001-2005 [2011 values]: US$ 262 for chlamydia [US$ 2021: 312] | US$ 262 for chlamydia per case | NA | NA |
US$ 197 for gonorrhoea [US$ 2021: 234] | US$ 197 for gonorrhoea per case | |||||
US$ 419 for syphilis [US$ 2021: 498] | US$ 419 for syphilis per case | |||||
US$ 289 for trichomoniasis [US$ 2021: 344] | US$ 289 for trichomoniasis per case | |||||
Shon et al. (Hepatitis A, B, C) | NA | NA | NA | NA | Hepatitis A: US$ 45.7 million/2008-2011 [US$ 2021: 54,3 million] | “[…] with indirect costs [opportunity costs lost as a result of medical care, or premature death and caregiver costs] accounting for the remaining 65 % during the observation period [2008-2011].” (Hepatitis A) |
Hepatitis B: US$ 607.8 million/2008-2011 [US$ 2021: 722.8 million] | “Indirect costs were estimated to be approximately 53.4 % of this total over the same period [2008-2011]” (Hepatitis B) | |||||
Hepatitis C: US$ 90.7 million/2008-2011 [US$ 2021: 107.8 million] | “[…] with indirect costs accounting for the remaining 42.0 % in 2011.” (Hepatitis C) [as reported in the original study] | |||||
Yang et al. (Hepatitis B) | Direct costs (direct formal medical costs, informal medical costs, and non-medical costs): 474,642 million KRW/year [2005] [or 0.474,642 trillion]** | NA [refer to the column on the right] | Indirect costs (time costs, caregiver costs, productivity losses): 1.463 trillion KRW/year incurred by HBV-related disease patients | 1.463 trillion KRW/year incurred by HBV-related disease patients | 1.937 trillion KRW/year | 75,5 % |
[US$ 2021: 558,639,140] | [US$ 2021: 1,721,832,880] | [US$ 2021: 1,721,832,880] | [US$ 2021: 2,279,692,610] |